REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients

REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients

REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients

Philip McCarthy, MD, Director of the Blood and Marrow Transplant Center at Roswell Park Comprehensive Cancer Center in Buffalo, NY, comments on the U.S. Food and Drug Administration (FDA)’s approval of REVLIMID (lenalidomide) maintenance therapy, after autologous stem cell transplant, for multiple myeloma. Dr. McCarthy, who authored cancer research that led to the FDA’s approval, also shares benefits of lenalidomide maintenance therapy for multiple myeloma patients.

Leave a Reply

Your email address will not be published. Required fields are marked *